

Bayesian Estimation of Propensity Scores for Integrating Multiple Cohorts with High-Dimensional Covariates

Subharup Guha^{1*} and Yi Li²

^{1*}Department of Biostatistics, University of Florida, 2004 Mowry Rd,
Gainesville, 32603, Florida, U.S.A..

²Department of Biostatistics, University of Michigan, 1415 Washington
Heights, Ann Arbor, 48109, Michigan, U.S.A..

*Corresponding author(s). E-mail(s): s.guha@ufl.edu;
Contributing authors: yili@umich.edu;

Abstract

Comparative meta-analyses of groups of subjects by integrating multiple observational studies rely on estimated propensity scores (PSs) to mitigate covariate imbalances. However, PS estimation grapples with the theoretical and practical challenges posed by high-dimensional covariates. Motivated by an integrative analysis of breast cancer patients across seven medical centers, this paper tackles the challenges of integrating multiple observational datasets. The proposed inferential technique, called Bayesian Motif Submatrices for Covariates (B-MS_C), addresses the curse of dimensionality by a hybrid of Bayesian and frequentist approaches. B-MS_C uses nonparametric Bayesian “Chinese restaurant” processes to eliminate redundancy in the high-dimensional covariates and discover latent *motifs* or lower-dimensional structures. With these motifs as potential predictors, standard regression techniques can be utilized to accurately infer the PSs and facilitate covariate-balanced group comparisons. Simulations and meta-analysis of the motivating cancer investigation demonstrate the efficacy of the B-MS_C approach to accurately estimate the propensity scores and efficiently address covariate imbalance when integrating observational health studies with high-dimensional covariates.

Keywords: B-MS_C, Data integration, Covariate imbalance, High-dimensional covariates, Hybrid Bayesian-frequentist

1 Introduction

The primary goal of integrative analysis across multiple observational health studies is to compare two or more exposure groups, delineated, for instance, by risk behavior, disease subtype, or treatment. Covariate imbalance can introduce bias into group comparisons [1–4], making covariate balance essential for valid comparisons [2, 3]. However, achieving covariate balance becomes more challenging when dealing with high-dimensional covariates.

This work is motivated by a multiple-study breast cancer investigation of female patients at seven nation-wide medical centers such as Mayo Clinic, University of Pittsburgh, and University of Miami. The data are publicly available for download from The Cancer Genome Atlas (TCGA) portal [5] and include 30 demographic and clinicopathological attributes, 20,531 mRNA expression levels and 24,776 copy number alteration (CNA) measurements. Some study-specific summaries are presented in Table 1 of Supporting Information. The inferential focus is the covariate-balanced comparisons of overall survival between infiltrating ductal carcinoma (IDC) and infiltrating lobular carcinoma (ILC), two major subtypes of breast cancer, by integrating the cancer cohorts from these seven centers. This knowledge may inform the development of viable guidelines for regulating targeted therapies and precision medicine among the breast cancer population, specifically tailored to different disease subtypes [6]. However, the highly unbalanced groups in Table 1 of Supporting Information present a challenge by confounding naive group comparisons. Indeed, the literature present conflicting findings due to the disease subtype’s confounding with, for example, cancer stage [7]. Therefore, it is imperative to implement covariate-balancing. The high-dimensional biomarkers, featured by these studies, pose additional challenges when ensuring covariate balance and analyzing data.

When analyzing single observational studies with two groups, the propensity score (PS) [3] is critical for covariate-balancing methods such as weighting and matching, and can be estimated in a robust manner [8]. However, propensity scores are not appropriate for data integration in multigroup, multistudy settings. In these investigations, [9] achieved covariate-balanced inferences by generalizing the PS to the *multiple propensity score* (MPS), defined as the probability of a patient or subject belonging to a study-group combination given their covariates. Due to their pivotal role in covariate-balanced data integration by weighting or matching, the unknown MPSs must be estimated. This is achieved by regressing the study-group combination on the covariates using frequentist or Bayesian methods. Ridge regression [10], lasso [11], adaptive lasso [12], group lasso [13], and the causal inference techniques of [14] and [15] are arguably the most popular regularization techniques in the frequentist causal inference paradigm. Bayesian methods for covariate-balanced inference are reviewed by [16], [17], [18], and [19], and include regularization methods [e.g., 20–22] and Bayesian Additive Regression Tree (BART) models [23]. However, these methods are often not as effective when the number of covariates is large.

High-dimensional covariates

While accurate MPS estimates are crucial to achieve covariate balance, they encounter significant challenges in high-dimensional observational studies such as the motivating TCGA breast cancer application. The pervasive collinearity in “small N -large p ” regression settings leads to unstable estimation and erroneous out-of-the-bag predictions. Generally, in high-dimensional regression settings, the predictors become virtually unidentifiable without robust priors, making it difficult to identify a sparse subset of covariates [24]. In TCGA studies, numerical collinearity arises due to the singularity of the sample variance-covariance matrix. This occurs because the number of covariates, such as demographic factors, clinicopathological data, mRNA expression, and CNA measurements, exceeds the sample size. Identifiability issues in regression coefficients prevent the determination, based solely on a likelihood function, of the true covariate associations with MPS.

For tackling these critical impediments to the accurate estimation of MPS as a first step of data integration, we propose a new Bayesian inferential procedure called Bayesian Motif Submatrices for Covariates (B-MSC). The method leverages non-parametric Bayesian Chinese restaurant processes (CRPs) [25, 26], and effectively eliminates redundancy in high-dimensional covariates. The method exhibits several advantages in comparison to existing techniques. Departing from existing Bayesian methods [e.g., 16, 17], our method is not “dogmatically Bayesian,” but rather a hybrid of Bayesian and frequentist solutions that permits flexible, out-of-the-box use of available software for regularization. Specifically, the proposed Bayesian nonparametric methods effectively mitigate the curse of dimensionality and unveil the latent structure or *motif* in the covariates. Then, using these identified motif elements as potential predictors, B-MSC applies existing frequentist or Bayesian regression techniques for lower-dimensional settings to estimate the MPS. This allows accurate and computationally efficient estimation of MPS and, subsequently, facilitates integrative comparative analyses of retrospective cohorts via weighting or matching methods.

Section 2 introduces some basic notation and theoretical assumptions. Section 2.1 describes the B-MSC hierarchical model and prior. A Bayesian inferential procedure, including a fast-mixing MCMC algorithm, is described in Section 2.2. Section 3 applies the proposed techniques to make integrative group comparisons with right-censored outcomes and high-dimensional covariates. We conduct simulations in Section 4 to demonstrate the efficacy of the B-MSC approach in dimension reduction and MPS estimation. Section 5 analyzes the high-dimensional TCGA breast cancer studies. Section 6 concludes with some remarks.

2 Bayesian Propensity Score Estimation for Meta-Analysis of Retrospective Cohorts with High-Dimensional Covariates

The investigation comprises J observational studies and focuses on comparing K groups of subjects. We assume J and K are small; in the context of the TCGA database discussed earlier, $J = 7$ and $K = 2$. For subject $i = 1, \dots, N$, let $Z_i \in \{1, \dots, K\}$ denote their groups and $S_i \in \{1, \dots, J\}$ be the observational study to which the i th

subject belongs. The database contains a large number of p covariates shared by all J studies. For the i th subject, let the vector of covariates, \mathbf{x}_i , belong to a space $\mathcal{X} \subset \mathcal{R}^p$ shared by the JK groups and studies. Further, let $\mathbf{x}_i = (\mathbf{x}_i^{[1]}, \mathbf{x}_i^{[2]})$, where vector $\mathbf{x}_i^{[1]}$ consists of p_1 continuous covariates, and $\mathbf{x}_i^{[2]}$ contains p_2 factor-valued covariates belonging to the set $\{1, 2, \dots, A\}$ for an integer $A > 1$; thus, $p = p_1 + p_2$. [9] defines the multiple propensity score or MPS as $\delta_{sz}(\mathbf{x}) = [S = s, Z = z \mid \mathbf{X} = \mathbf{x}]_+$ for $(s, z) \in \Sigma \equiv \{1, \dots, J\} \times \{1, \dots, K\}$ and $\mathbf{x} \in \mathcal{X}$. In many applications, both p_1 and p_2 are large, and $\min\{p_1, p_2\}$ far exceeds N . Stacking these N row vectors, we obtain an $N \times p_1$ matrix, $\mathbf{X}^{[1]}$, of continuous covariates and an $N \times p_2$ matrix, $\mathbf{X}^{[2]}$, of factor covariates. Since the covariates are subsequently used in regression settings, the columns of continuous submatrix $\mathbf{X}^{[1]}$ are assumed to be empirically standardized to zero means and unit standard deviations. It is trivial to extend this framework to accommodate additional factor variables, e.g., with binary and trinary covariates, we set $\mathbf{x}_i = (\mathbf{x}_i^{[1]}, \mathbf{x}_i^{[2]}, \mathbf{x}_i^{[3]})$ with $A_2 = 2$ and $A_3 = 3$. Denote by $T_i^{(z)}$ the counterfactual outcome if Z_i were z . The realized outcome is $T_i = T_i^{(Z_i)}$. Denoting by C_i the censoring time, $Y_i = \min\{T_i^{(Z_i)}, C_i\}$ is the observed survival time with event indicator $\vartheta_i = \mathcal{I}(T_i^{(Z_i)} \leq C_i)$, where $\mathcal{I}(\cdot)$ is an indicator function. In the TCGA datasets, submatrices $\mathbf{X}^{[1]}$ and $\mathbf{X}^{[2]}$ of the covariate matrix \mathbf{X} include high-dimensional demographic and clinicopathological variables in addition to mRNA and CNA biomarkers. The CNA measurements are coarsened as binary factors: 1 (no CNA) or 2 (some CNA), i.e., $A = 2$. Also in this context, $T_i^{(1)}$ and $T_i^{(2)}$ represent the counterfactual outcomes if patient i was diagnosed with disease subtype IDC and ILC, respectively; $\vartheta_i = 1$ if Y_i , the observed survival time of the i th patient, is uncensored, and equals 0 otherwise.

As index (i) contains no meaningful information, the individual measurements are a random sample from an *observed distribution*, $[S, Z, \mathbf{X}, T]_+$, where the symbol $[\cdot]_+$ represents distributions or densities under the observed population. Following [27], we make the following assumptions: (a) **Stable unit treatment value**: a subject's study and group memberships do not influence the potential outcomes of any other subject. Furthermore, each subject has K potential outcomes of which only one is observed; (b) **Study-specific weak unconfoundedness**: Conditional on study S and covariate \mathbf{X} , the event $[Z = z]$ is independent of counterfactual outcome $T^{(z)}$ for all $z = 1, \dots, K$; and (c) **Positivity**: Joint density $[S = s, Z = z, \mathbf{X} = \mathbf{x}]_+$ is strictly positive for all (s, z, \mathbf{x}) , ensuring that the study-group memberships and covariates do not have non-stochastic, mathematical relationships.

2.1 Bayesian motif submatrices for dimension reduction

B-MSM utilizes the sparsity-inducing property of Bayesian mixture models to detect lower-dimensional structure in the covariate submatrices. We perform bidirectional, unsupervised global clustering of $\mathbf{X}^{[1]}$ and $\mathbf{X}^{[2]}$. A nonparametric Chinese restaurant process (CRP), denoted by $\mathcal{C}_r^{[1]}$, discovers $q_r^{[1]}$ latent subpopulations or *cliques* among the N rows of submatrix $\mathbf{X}^{[1]}$. Simultaneously, another CRP, $\mathcal{C}_c^{[1]}$, discovers $q_c^{[1]}$ latent *clusters* among the p_1 continuous covariates (submatrix $\mathbf{X}^{[1]}$ columns). This gives a “denoised” lower-dimensional version of submatrix $\mathbf{X}^{[1]}$ called the *motif submatrix*,

$\Phi^{[1]}$, of dimension $q_r^{[1]} \times q_c^{[1]}$. For the factor covariate matrix $\mathbf{X}^{[2]}$, another set of CRPs, $\mathcal{C}_r^{[2]}$ and $\mathcal{C}_c^{[2]}$, performs global unsupervised clustering of the rows and columns of $\mathbf{X}^{[2]}$ to give a $q_r^{[2]} \times q_c^{[2]}$ motif submatrix, $\Phi^{[2]}$.

CRPs attempt to reverse the curse of dimensionality by guaranteeing with high probability that $q_r^{[1]} \ll N$ and $q_c^{[1]} \ll p_1$, while allowing the number of cliques and clusters to be apriori unknown. Instead of the highly collinear covariates $\mathbf{X} = (\mathbf{X}^{[1]}, \mathbf{X}^{[2]})$, the estimated motif matrices act as covariates to reliably infer the MPS, as demonstrated later by simulation studies. The meta-analytical weighting methods outlined in Introduction are then employed to make covariate-balanced comparisons of the health outcomes of the K groups.

For $g = 1, 2$, biomarker clusters are likely to exist in submatrix $\mathbf{X}^{[g]}$ because N is much smaller than p_g ; since the rank of $\mathbf{X}^{[g]}$ is N or less, its p_g columns have high redundancy. Closely related to some aspects of the proposed B-MSA approach are global clustering algorithms for continuous covariate matrices [e.g., 28, 29], which assume that the matrix rows and columns can be independently permuted to reveal the underlying lower-dimensional signal. Alternatively, B-MSA can be viewed as an adaptation of local clustering algorithms for continuous covariates [24, 30] and binary covariates [31] to multiple factor levels and computationally efficient global clustering implementations. From a scientific perspective, biomarkers do not act in isolation but in concert to perform biological functions, resulting in similar biomarker profiles [e.g., 32]. Biomarkers exhibiting similar patterns in high-dimensional genomic, epigenomic, and microbiome data have been exploited to achieve dimension reduction via mixture models [e.g., 33, 34]. However, to our knowledge, this phenomenon has not been fully utilized to achieve efficient inferences in covariate-balanced integrative analyses.

More formally, for the columns of covariate submatrix $\mathbf{X}^{[g]}$, where $g = 1, 2$, we envision *biomarker-cluster mapping variables*, $c_1^{[g]}, \dots, c_{p_g}^{[g]}$, with $c_i^{[g]} = u$ representing the event that the j th biomarker of $\mathbf{X}^{[g]}$ is allocated to the u th latent cluster, for biomarker $j = 1, \dots, p_g$, and cluster $u = 1, \dots, q_c^{[g]}$. For a positive mass parameter $\alpha_c^{[g]}$, CRP prior $\mathcal{C}_c^{[g]}(\alpha_c^{[g]})$ assigns the following PMF to the vector of p_g cluster mapping variables:

$$[\mathbf{c}^{[g]} | \alpha_c^{[g]}] = \frac{\Gamma(\alpha_c^{[g]}) (\alpha_c^{[g]})^{q_c^{[g]}}}{\Gamma(\alpha_c^{[g]} + p_g)} \prod_{u=1}^{q_c^{[g]}} \Gamma(m_u^{[g]}), \quad \mathbf{c}^{[g]} \in \mathcal{Q}_{p_g},$$

where $m_u^{[g]}$ is the number of biomarkers belonging to the u th latent cluster in mapping vector $\mathbf{c}^{[g]}$, and \mathcal{Q}_p is the set of all possible partitions of p objects into one or more sets [26]. Dimension reduction occurs because the random number of clusters, $q_c^{[g]}$, is approximately equal to $\alpha_c^{[g]} \log(p_g)$ as p_g is sufficiently large [25].

Analogously, for the N rows of covariate submatrix $\mathbf{X}^{[g]}$, there exists *subject-clique mapping variables*, $r_1^{[g]}, \dots, r_n^{[g]}$, with $r_i^{[g]} = u$ representing the event that the i th subject is allocated to the u th latent clique, where $i = 1, \dots, N$, and $u = 1, \dots, q_r^{[g]}$. For a positive mass parameter $\alpha_r^{[g]}$, the vector of clique mapping variables is given a CRF prior, $\mathbf{r}^{[g]} \sim \mathcal{C}_r^{[g]}(\alpha_r^{[g]})$, for which the unknown number of cliques, $q_r^{[g]}$, is asymptotically lower order than N .

Motif submatrices

Unlike the CRP allocation models for dimension reduction, the priors for motif submatrices $\Phi^{[1]}$ and $\Phi^{[2]}$ depend on the covariate types (continuous or factor) of submatrices $\mathbf{X}^{[1]}$ and $\mathbf{X}^{[2]}$. Consider motif submatrix $\Phi^{[1]} = (\phi_{rc}^{[1]})$. We assume $\phi_{rc}^{[1]} \stackrel{\text{i.i.d.}}{\sim} N(0, \tau^2)$ for $r = 1, \dots, q_r^{[1]}$ and $c = 1, \dots, q_c^{[1]}$, with τ^2 assigned an inverse gamma hyperprior. Next, consider motif submatrix $\Phi^{[2]} = (\phi_{rc}^{[2]})$. Submatrix $\mathbf{X}^{[2]}$ consists of factors with levels belonging to $\{1, 2, \dots, A\}$. Therefore, for $r = 1, \dots, q_r^{[2]}$ and $c = 1, \dots, q_c^{[2]}$, we assume $\phi_{rc}^{[2]} \stackrel{\text{i.i.d.}}{\sim} \mathcal{B}_A(\mathbf{g})$, a generalized Bernoulli or categorical distribution on A categories, with the probability vector $\mathbf{g} = (g_1, \dots, g_A)$ given a Dirichlet distribution hyperprior. This implies that motif submatrix $\Phi^{[2]}$ also consists of factors taking values in $\{1, 2, \dots, A\}$.

Likelihood functions for covariates

We model the matrix $\mathbf{X}^{[1]}$ elements as noisy versions of the mapped elements of $\Phi^{[1]}$. We specify distributional assumptions guaranteeing that all biomarkers in a cluster have similar, but not necessarily identical, column profiles in $\mathbf{X}^{[g]}$ and these biomarkers map to the same column of motif submatrix $\Phi^{[g]}$. Additionally, all subjects in a clique have similar, but not necessarily identical, row profiles in $\mathbf{X}^{[g]}$ and these subjects map to the same row of $\Phi^{[g]}$. The elements of submatrix $\mathbf{X}^{[1]}$ are conditionally Gaussian: $x_{ij}^{[1]} | \Phi^{[1]}, \mathbf{c}^{[1]}, \mathbf{r}^{[1]} \stackrel{\text{indep}}{\sim} N(\phi_{r_i^{[1]} c_j^{[1]}}^{[1]}, \sigma^2)$, where $i = 1, \dots, N$, $j = 1, \dots, p_1$, and σ^2 has a truncated inverse gamma hyperprior that ensures R^2 is sufficiently large. At first glance, the Gaussian likelihood and common variance σ^2 may appear to be a strong parametric assumption. However, if the biomarker and subject labels are non-informative, the assumed CRP priors for the clusters and cliques constitute a semi-parametric model for the $\mathbf{X}^{[1]}$ elements and the arbitrary, true underlying distribution of the i.i.d. submatrix elements is consistently inferred a posteriori [35].

The matrix $\mathbf{X}^{[2]}$ elements as possibly corrupted versions of the mapped motif elements with low probabilities of *corruption* or covariate-motif mismatch, i.e., $x_{ij}^{[2]} \neq \phi_{r_i^{[2]} c_j^{[2]}}^{[2]}$. The elements of factor submatrix $\mathbf{X}^{[2]}$ are related to the mapped elements of $\Phi^{[2]}$ as follows: $P\left(x_{ij}^{[2]} = x \mid \phi_{r_i^{[2]} c_j^{[2]}}^{[2]} = \phi, \Phi^{[2]}, \mathbf{c}^{[2]}, \mathbf{r}^{[2]}, \mathbf{W}\right) = w_{\phi x}$, $\phi, x \in \{1, 2, \dots, A\}$ for a *corruption probability matrix* $\mathbf{W} = (w_{\phi x})$ of dimension $A \times A$. Low corruption levels are achieved by a diagonally dominant \mathbf{W} . Since matrix \mathbf{W} is row-stochastic, row vectors $\mathbf{w}_1, \dots, \mathbf{w}_A$ are assigned independent priors on the unit simplex in \mathcal{R}^A . Let $\mathbf{1}$ be the vector of A ones. For $\phi = 1, \dots, A$, let $\mathbf{1}_\phi$ be the vector in \mathcal{R}^A with the ϕ th element equal to 1 and the other $(A - 1)$ elements equal to zero. The ϕ th row vector of \mathbf{W} is $\mathbf{w}_\phi = l_\phi \mathbf{1}_\phi + (1 - l_\phi) \tilde{\mathbf{w}}_\phi$, where $\tilde{\mathbf{w}}_\phi \sim \mathcal{D}_A(\alpha \mathbf{1}/A)$ and $l_\phi \sim \text{beta}(l_\alpha, l_\beta) \cdot \mathcal{I}(l_s > l^*)$, for prespecified constants l^* , l_α and l_β , and \mathcal{D}_A representing a Dirichlet distribution in \mathcal{R}^A . The condition $l^* > 0.5$ implies \mathbf{W} is diagonally dominant. Through extensive simulations, we find that $l^* > 0.85$ produces sufficiently “tight” clusters and cliques in submatrix $\mathbf{X}^{[2]}$.

2.2 Estimating MPS in the presence of high-dimensional covariates

For integrative covariate-balanced inferences, we propose a hybrid Bayesian and frequentist approach for MPS estimation. Since the MPS is $\delta_{sz}(\mathbf{x}) = [S = s, Z = z \mid \mathbf{X} = \mathbf{x}]_+$ we could estimate it in theory by regressing (S_i, Z_i) on the p -dimensional covariate \mathbf{x}_i ($i = 1, \dots, N$). Indeed, for low-dimensional covariates, the MPS is accurately estimated using parametric (e.g., multinomial logistic) or nonparametric, Bayesian or frequentist regression models. Unsurprisingly, this strategy is inefficient or even untenable in the presence of high-dimensional covariates. When p is large, we propose the following two-step inferential procedure using the lower-dimensional approximation of \mathbf{x}_i as predictor:

Step 1 We first obtain MCMC estimates $\hat{\Phi}^{[1]}$ and $\hat{\Phi}^{[2]}$ of the lower-dimensional motif submatrices and the least squares allocations $\hat{\mathbf{r}}^{[1]}$ and $\hat{\mathbf{r}}^{[2]}$ of the clique mapping variables:

Step 1a Following initialization using naive estimation strategies, the B-MSM model parameters are iteratively updated using MCMC techniques until the chain converges to the posterior. In Supporting Information, we summarize a computationally efficient, fast-mixing MCMC algorithm. Exploiting the B-MSM model structure, the MCMC sampler can be parallelized to separately update the non-intersecting parameters related to submatrices $\mathbf{X}^{[1]}$ and $\mathbf{X}^{[2]}$. Using the post-burn-in MCMC samples, Bayes estimates are computed for the posterior probability of each biomarker pair belonging to the same cluster and each subject pair belonging to the same clique. Following [28], these probabilities are used to compute point estimates for the cluster and clique mapping variables, called *least-squares allocations*. The estimated cluster variables are denoted by $\hat{\mathbf{c}}^{[1]}$ and $\hat{\mathbf{c}}^{[2]}$. The estimated clique variables are denoted by $\hat{\mathbf{r}}^{[1]}$ and $\hat{\mathbf{r}}^{[2]}$.

Step 1b Setting the cluster and clique mapping variables equal to their least-squares allocations, a second MCMC sample is generated and post-processed to obtain Bayes estimates of motif submatrices, denoted by $\hat{\Phi}^{[1]}$ and $\hat{\Phi}^{[2]}$.

Step 2 Conditional on Bayes estimates $\hat{\Phi}^{[1]}$ and $\hat{\Phi}^{[2]}$ of the lower-dimensional motif submatrices and the least squares allocations $\hat{\mathbf{r}}^{[1]}$ and $\hat{\mathbf{r}}^{[2]}$ of the clique mapping variables, the B-MSM approach regresses (S_i, Z_i) on the subject-specific motif vector $(\hat{\phi}_{\hat{\mathbf{r}}_i^{[1]}}^{[1]}, \hat{\phi}_{\hat{\mathbf{r}}_i^{[2]}}^{[2]})$ of length $q_c^{[1]} + q_c^{[2]} \ll p$. Commonly used regression techniques for low- or high-dimensional covariate-balanced inference that have been implemented in R packages, e.g., multinomial logistic regression, random forests, ridge regression, lasso, adaptive lasso, group lasso, and BART, may then be employed to efficiently discover the relationship between the study-group memberships and the clique-specific rows of the motif matrices. We then obtain MPS estimate $\hat{\delta}_{sz}(\mathbf{x}_i) = \hat{\delta}_{sz}(\hat{\phi}_{\hat{\mathbf{r}}_i^{[1]}}^{[1]}, \hat{\phi}_{\hat{\mathbf{r}}_i^{[2]}}^{[2]})$, for $s = 1, \dots, J$, $z = 1, \dots, K$. Although other methods like PCA regression could potentially be used, they are perhaps less popular in the causal inference literature because they do not perform feature selection that helps deduce the sparse associations (if any) between MPS and the covariates or their clusters; in that sense, the inferred regression relationships lack scientific interpretability with these methods [16, 24].

3 Application: Covariate-balanced survival function estimation by meta-analyzing right-censored outcomes

After the MPS estimates are available, weighting methods may be applied to achieve covariate-balanced inferences. In single observational studies, since weighting inferences utilizing inverse probability weights (IPWs) may be unstable when some subjects have very small PSs [36], several authors [e.g., 4, 36–38] have proposed alternative PS-based weighting strategies. [9] introduced a general framework that extends several weighting methods in the literature to effectuate covariate-balanced integrative analyses of multiple cohorts with multiple groups. We briefly summarize the methodology here. For any weighting method, the *unnormalized weight function*, denoted by $\tilde{\rho}(s, z, \mathbf{x})$, and the *empirically normalized balancing weight* of the i th subject, $\bar{\rho}_i = N\tilde{\rho}(s_i, z_i, \mathbf{x}_i) / \sum_{l=1}^N \tilde{\rho}(s_l, z_l, \mathbf{x}_l)$, can be computed, producing sample weights that sum to N . For example, $\tilde{\rho}(s, z, \mathbf{x}) = 1/\hat{\delta}_{sz}(\mathbf{x})$ extends IPWs and generalized IPWs [27] to *integrative combined* (IC) weights in meta-analytical settings. Similarly, generalized overlap weights [36] can be extended to *integrative generalized overlap* (IGO) weights by assuming $\tilde{\rho}(s, z, \mathbf{x}) = \hat{\delta}_{sz}^{-1}(\mathbf{x}) / \sum_{s'=1}^J \sum_{z'=1}^K \hat{\delta}_{s'z'}^{-1}(\mathbf{x})$. In addition to incorporating equal amounts of information from the J studies, most weighting methods provide accurate inferences only for hypothetical pseudo-populations in which the K groups are equally prevalent. For natural populations with unequally distributed groups, [9] developed FLEXOR weights to create more realistic pseudo-populations. Suppose the relative group prevalence in the natural population of interest is the probability vector, $\boldsymbol{\theta} = (\theta_1, \dots, \theta_K)$, e.g., in the TCGA breast cancer studies, $\boldsymbol{\theta} = (8/9, 1/9)$ matches the known U.S. proportions of breast cancer subtypes IDC and ILC. Then $\tilde{\rho}(s, z, \mathbf{x}) = \hat{\delta}_{sz}^{-1}(\mathbf{x}) \left(\sum_{s'=1}^J \sum_{z'=1}^K \frac{\check{\gamma}_{s'}^2 \theta_{z'}}{\hat{\delta}_{s'z'}(\mathbf{x})} \right)^{-1}$ gives the FLEXOR pseudo-population with the characteristics: (i) the relative weights of the groups matches that of the natural population; (ii) probability vector $\check{\boldsymbol{\gamma}} = (\check{\gamma}_1, \dots, \check{\gamma}_J)$ represents optimal study weights and is easily estimated by an efficient numerical procedure with negligible computational costs; and (iii) FLEXOR maximizes the effective sample size in a broad-ranging family encompassing many meta-analytical weighting methods, including IC and IGO weights.

Covariate-balanced weighted survival analysis

As an application, we apply the proposed MPS estimation, in conjunction with the weighting methods of [9], to analyze right-censored outcomes with unbalanced high-dimensional covariates. Consider survival functions of the counterfactual outcomes $T^{(z)}$ in the pseudo-population: $S^{(z)}(t) = \mathbb{P}[T^{(z)} > t]$ for $t > 0$ and group $z = 1, \dots, K$. As previously noted, realized outcome $T = T^{(Z)}$. Analogously to the weak unconfoundedness assumption for the observed population, we make an identical assumption for the pseudo-population. That is, $[T|S, Z, \mathbf{X}] = [T|S, Z, \mathbf{X}]_+$, where $[\cdot]$ denotes pseudo-population densities. Unlike the observed population, the covariate-balanced pseudo-population gives us $[T | Z = z] = [T^{(z)}]$, facilitating weighted estimators of different features of pseudo-population potential outcomes. Specifically, using the

empirically normalized generalized balancing weights, the single-study estimator of [39] can be extended in a straightforward manner to obtain the *balance-weighted Kaplan-Meier estimator* (BKME) of pseudo-population survival function $S^{(z)}(t)$ as follows. Among the N subjects, suppose the observed failures, with possible ties, occur at the distinct times $0 < t_1 < \dots < t_D$. For the z th group, using the empirically normalized generalized balancing weights, the weighted number of deaths and the weighted number of subjects at risk at time t_j are, respectively, $d_j^{(z)} = N \sum_{i:Y_i=t_j, \vartheta_i=1} \bar{\rho}_i \mathcal{I}(Z_i = z)$ and $R_j^{(z)} = N \sum_{i:Y_i \geq t_j} \bar{\rho}_i \mathcal{I}(Z_i = z)$, for $j = 1, \dots, D$. The BKME of the z th survival function in the pseudo-population is then

$$\hat{S}^{(z)}(t) = \prod_{j:t_j \leq t} (1 - d_j^{(z)}/R_j^{(z)}) \quad (1)$$

Variance estimate $\widehat{\text{Var}}(\hat{S}^{(z)}(t)) = (\hat{S}^{(z)}(t))^2 \prod_{j:t_j \leq t} \frac{d_j^{(z)}}{R_j^{(z)}(R_j^{(z)} - d_j^{(z)})}$ is used for point-wise confidence intervals. The BKME is consistent and asymptotic normal as an estimator of $S^{(z)}(t)$ and its variance estimate is consistent [40]. If some groups are undersampled, large-sample inferences may not be valid for those groups. Using B bootstrap samples of size N each, we could apply nonparametric bootstrap methods to estimate the standard error of BKME and construct asymptotic or distribution-free confidence intervals for the group-specific pseudo-population survival functions.

4 Simulation Study

We aimed to evaluate the effectiveness of the proposed B-MSA approach in (i) achieving dimension reduction in \mathbf{X} , (ii) inferring the clique memberships of additional test case patients, and (iii) when used in conjunction with existing Bayesian or frequentist regression approaches, inferring the MPS of the training and test set subjects, compared to using the same regression approaches with \mathbf{X} as the high-dimensional predictor. Since the primary focus is “outcome-free” dimension reduction and MPS estimation, no responses were generated in this simulation study. Using the actual $p_1 = 758$ continuous (intercept + 750 most variable mRNA biomarkers + 7 clinicopathological) and $p_2 = 522$ binary (500 most variable CNA biomarkers + 22 binary clinicopathological or socioeconomic) covariates of the seven TCGA breast cancer studies, we generated the study-group memberships of $R = 500$ simulated datasets. We examined two scenarios (labeled “high” and “low”) characterized by the degree of association between MPS and its predictors, and determined by a simulation parameter, μ . Each dataset consisted of $J = 4$ observational studies and $K = 2$ groups to match the TCGA application.

Specifically, we sampled with replacement the $p = p_1 + p_2 = 1,280$ covariates of the TCGA breast cancer patients and randomly allocated the $\tilde{N} = 450$ subjects of each artificial dataset to $JK = 14$ study-group combinations. For dataset $r = 1, \dots, 500$, and association parameter μ belonging to $\{10, 15\}$, we generated:

1. **Covariate matrix** For $i = 1, \dots, \tilde{N}$, covariate vector $\mathbf{x}_{ir} = (x_{i1r}, \dots, x_{ipr})'$ was sampled with replacement from the TCGA datasets to obtain matrix \mathbf{X}_r of dimension $\tilde{N} \times p$, comprising $p = 1, 280$ binary or continuous covariates.
2. **True MPS predictors** Without exception, the rank of \mathbf{X}_r was \tilde{N} in all the generated datasets. Let the singular value decomposition of \mathbf{X}_r be $\mathbf{H}_r \mathbf{D}_r \mathbf{B}_r'$ where \mathbf{H}_r is an $\tilde{N} \times \tilde{N}$ matrix with orthonormal columns, \mathbf{D}_r is a $\tilde{N} \times \tilde{N}$ diagonal matrix with positive diagonal entries, and \mathbf{B}_r is a $p \times \tilde{N}$ matrix with orthonormal columns. Setting $\tilde{n} = 50 < \tilde{N}$, we let $\hat{\mathbf{X}}_r = \hat{\mathbf{H}}_r \hat{\mathbf{D}}_r (\hat{\mathbf{B}}_r)^T$, where $\hat{\mathbf{D}}_r$ is a $\tilde{n} \times \tilde{n}$ diagonal matrix containing the highest \tilde{n} diagonal elements of \mathbf{D}_r , and $\hat{\mathbf{H}}_r$ and $\hat{\mathbf{B}}_r$ extract the matching \tilde{n} columns of \mathbf{H}_r and \mathbf{B}_r .
Each of the p covariates in matrix $\hat{\mathbf{X}}_r$ was randomly designated as either a non-predictor, linear, or quadratic predictor of the true MPS. For covariate $j = 1, \dots, p$, we independently generated category $H_{jr} \in \{0, 1, 2\}$ with probabilities 0.5, 0.25, and 0.25, respectively, signifying that the j th covariate is a non-predictor, linear and quadratic predictor. Let the $\tilde{H}_r = \sum_{j=1}^p \mathcal{I}(H_{jr} > 0)$ linear or quadratic regression predictors derived from $\hat{\mathbf{X}}_r$ be arranged in an $\tilde{N} \times (\tilde{H}_r + 1)$ matrix denoted by $\mathbf{Q}_r = (q_{ilr})$, with column 1 consisting of \tilde{N} ones.
3. **True MPS and study-group memberships** Study s_{ir} and group z_{ir} were generated:
 - (a) *Regression coefficients* Let $(s, z) = (1, 1)$ be the reference study-group combination. For the remaining $(JK - 1)$ combinations, regression vectors $\mathbf{v}_{s_zr} = (v_{sz0r}, \dots, v_{sz\tilde{H}_r,r})'$ $\stackrel{\text{i.i.d.}}{\sim} N_{\tilde{H}_r+1}(\mathbf{0}, \mathbf{\Sigma} + \mu^2 \mathbf{I}_{\tilde{H}_r+1})$, where $\mathbf{\Sigma}^{-1} = \mathbf{Q}_r' \mathbf{Q}_r$, and let $\eta_{is_zr} = \sum_{l=0}^{\tilde{H}_r} v_{szlr} q_{ilr}$. For the reference combination, $\eta_{i11r} = 0$. Setting $\mu = 10$ (15) produced low (high) signal-to-noise ratios.
 - (b) *True MPS* For the i th subject, set $\delta_{s_zr}(\mathbf{x}_{ir}) = \exp(\eta_{is_zr}) / \sum_{s'=1}^J \sum_{z'=1}^K \exp(\eta_{is'z'r})$. Evaluate true MPS vector, $\boldsymbol{\delta}_r(\mathbf{x}_{ir}) = \{\delta_{s_zr}(\mathbf{x}_{ir}) : s = 1, \dots, J, z = 1, \dots, K\}$.
 - (c) *Study-group memberships* Independently generate (s_{ir}, z_{ir}) from the categorical distribution with probability vector $\boldsymbol{\delta}_r(\mathbf{x}_{ir})$.

Disregarding knowledge of all simulation parameters, we meta-analyzed the \tilde{N} study-group memberships and $\tilde{N} \times p$ covariate matrix \mathbf{X}_r of each artificial dataset using the proposed B-MSC methodology. First, the $\tilde{N} = 450$ subjects of each dataset were randomly split into training and test samples in a 4 : 1 ratio, so that $\tilde{N}_{\text{train}} = 360$ and $\tilde{N}_{\text{test}} = 90$. The MCMC algorithm of Supplementary Material was applied to generate posterior samples. We discarded a burn-in of 10,000 MCMC samples and used 50,000 post-burn-in draws for posterior inferences. Convergence was informally assessed by trace plots of hyperparameters to determine the appropriate MCMC sample sizes. The post-burn-in MCMC draws was processed to estimate the lower-dimensional motif submatrices $\Phi^{[1]}$ and $\Phi^{[2]}$ as described previously. Then, the estimated motif submatrices and study-group memberships of the \tilde{N}_{train} subjects were used to infer the MPS using various regression techniques, namely, ridge regression, lasso, adaptive lasso, group lasso, random forests, multinomial logistic regression, and BART techniques implemented in the R packages `glmnet`, `randomForest`, `nnet`, and `BART`, respectively. Next, focusing on the \tilde{N}_{test} subjects, posterior estimates of the latent cliques $\hat{r}_i^{[1]}$ and

$\hat{r}_i^{[2]}$ and motif vectors $(\hat{\phi}_{\hat{r}_i^{[1]}}^{[1]}, \hat{\phi}_{\hat{r}_i^{[2]}}^{[2]})$ of length $\hat{q}_r^{[1]} + \hat{q}_r^{[2]}$ were estimated from their p fully observed covariates, \mathbf{x}_i , using the Supporting Information MCMC algorithm. Finally, for these test case subjects, the estimated MPS vector $\hat{\delta}(\mathbf{x}_i)$ of length JK were computed using only motif vectors $(\hat{\phi}_{\hat{r}_i^{[1]}}^{[1]}, \hat{\phi}_{\hat{r}_i^{[2]}}^{[2]})$.

For the $p_1 = 758$ continuous covariates, the average number of estimated clusters, $\hat{q}_c^{[1]}$, of the 500 datasets was 173.8 with a standard error of 0.2. For the $p_2 = 522$ binary covariates, the average number of estimated clusters, $\hat{q}_c^{[2]}$, was 38.3 with a standard error of 0.2. In other words, the estimated motif submatrices of B-MSc were substantially smaller than the full set of covariates. Next, for each dataset, and using the estimated motif matrices of the training samples, we evaluated the accuracy of the estimated cliques $\hat{r}_i^{[g]}$ of the test samples using a measure called the *parity*, $\Delta^{[g]}$, for covariate types $g = 1, 2$. Since the “true” cliques of the TCGA datasets are unknown, the parity compares two quantities: (a) the estimated clique motifs of the test subjects when the B-MSc model is fitted to the \tilde{N}_{train} subjects and applied to the \tilde{N}_{test} subjects, versus (b) the estimated clique motifs for the same test subjects when the B-MSc model is fitted to all \tilde{N} subjects. A high parity indicates that out-of-sample individuals are mapped to their latent cliques in a reliable manner.

More specifically, when the entire sample of \tilde{N} subjects is used to estimate the unknown B-MSc model parameters, denote the subject-specific latent cliques by $\tilde{r}_i^{[1]}$ and $\tilde{r}_i^{[2]}$, and the motif vectors by $(\tilde{\phi}_{\tilde{r}_i^{[1]}}^{[1]}, \tilde{\phi}_{\tilde{r}_i^{[2]}}^{[2]})$ of length $\tilde{q}_r^{[1]} + \tilde{q}_r^{[2]}$. For the continuous covariates $\mathbf{X}_r^{[1]}$, the parity $\Delta_r^{[1]}$ is defined as the correlation between the motif element pairs, $(\tilde{\phi}_{\tilde{r}_i^{[1]}\tilde{c}_j^{[1]}}^{[1]}, \hat{\phi}_{\hat{r}_i^{[1]}\hat{c}_j^{[1]}}^{[1]})$, over all $j = 1, \dots, p_1$, and test cases i . Notice that the first term depends on latent clique $\tilde{r}_i^{[1]}$ whereas the second term depends on latent clique $\hat{r}_i^{[1]}$. For the binary covariates $\mathbf{X}_r^{[2]}$, the parity $\Delta_r^{[2]}$ is the proportion of matches between the motif elements, i.e., the average of $\mathcal{I}(\tilde{\phi}_{\tilde{r}_i^{[1]}\tilde{c}_j^{[1]}}^{[1]} = \hat{\phi}_{\hat{r}_i^{[1]}\hat{c}_j^{[1]}}^{[1]})$ over all $j = 1, \dots, p_2$, and test cases i . Averaging over the 500 datasets in the low association simulation scenario ($\mu = 10$), the average clique parity $\Delta_r^{[g]}$ % of test cases was 64.79% with an estimated standard error of 0.1% for continuous covariates ($g = 1$), and 97.00% with an estimated standard error of 0.03% for binary covariates ($g = 2$). Irrespective of the covariate type, the test case latent clique characteristics when \tilde{N}_{train} samples were used to fit the B-MSc model, were similar to the latent clique characteristics when all \tilde{N} samples were used to train the B-MSc model. For perspective, in the case of binary covariates, a parity exceeding 96% corresponds to fewer than 1,883 mismatches among the 47,070 bits of the test subjects’ motifs, demonstrating the high reliability of inferring the latent cliques. The results were similar in the high association simulation scenario.

For the r th dataset, the study-group memberships and estimated motif submatrices of the B-MSc method, estimated using only the \tilde{N}_{train} subjects, were used to estimate MPS using different regression techniques. The correlation between the estimate $\hat{\delta}_{szr}(\mathbf{x}_{ir})$ and true MPS, $\delta_{szr}(\mathbf{x}_{ir})$, $i = 1, \dots, \tilde{N}$, was computed for each (s, z) combination. For the low association scenario ($\mu = 10$), the average correlations over the $R = 500$ datasets are reported in the columns labeled “B-MSc” in Tables 1-3.

BART					
		Training cases		Test cases	
		B-MSC	Full	B-MSC	Full
Study 1	Group 1	38.0 (1.1)	20.6 (1.0)	37.1 (1.2)	17.9 (1.1)
	Group 2	52.8 (1.3)	28.7 (1.1)	51.0 (1.3)	22.3 (1.3)
	Group 3	53.0 (1.3)	30.4 (1.1)	51.1 (1.3)	23.2 (1.3)
	Group 4	52.5 (1.2)	29.5 (1.1)	49.8 (1.4)	22.2 (1.3)
Study 2	Group 1	52.8 (1.3)	31.0 (1.1)	50.2 (1.4)	24.0 (1.2)
	Group 2	52.5 (1.4)	29.6 (1.1)	49.9 (1.4)	23.7 (1.3)
	Group 3	50.4 (1.3)	31.5 (1.1)	48.2 (1.4)	25.4 (1.2)
	Group 4	52.4 (1.3)	29.5 (1.1)	50.5 (1.4)	23.5 (1.2)

Random forests					
		Training cases		Test cases	
		B-MSC	Full	B-MSC	Full
Study 1	Group 1	23.3 (0.8)	19.0 (1.1)	24.1 (0.9)	22.5 (1.3)
	Group 2	37.3 (1.1)	24.8 (1.3)	39.0 (1.2)	27.2 (1.4)
	Group 3	38.9 (1.1)	29.2 (1.2)	38.6 (1.2)	32.1 (1.4)
	Group 4	37.5 (1.1)	27.2 (1.3)	38.1 (1.2)	29.0 (1.5)
Study 2	Group 1	37.1 (1.1)	27.0 (1.3)	36.7 (1.2)	30.4 (1.4)
	Group 2	37.5 (1.2)	26.0 (1.3)	37.8 (1.3)	29.5 (1.4)
	Group 3	36.4 (1.1)	28.9 (1.3)	37.1 (1.2)	32.1 (1.4)
	Group 4	37.9 (1.1)	25.7 (1.3)	38.8 (1.3)	29.1 (1.4)

Table 1: In the *low association* simulation scenario, accuracy of inferred MPS utilizing the smaller motif submatrices of the proposed B-MSC method as the covariates compared to the high-dimensional set of covariates (“Full”). For **BART** and **random forest** estimation procedures (row block) and study-group combination (row), the displayed numbers are the percentage correlations between the true and estimated MPS of the 360 training and 90 test cases (column blocks), averaged over 500 artificial datasets. Shown in parentheses are the estimated standard errors of the correlations. Separately for the training samples and test samples of each row, a covariate set (B-MSC or Full) with a significantly higher correlation is highlighted in bold.

For comparison, the columns labeled “Full” display the corresponding numbers when all p (fully observed) covariates are used as MPS predictors. Although the multinomial logistic regression model implemented in the `nnet` package was easily able to accommodate the smaller motif submatrices of B-MSC, the full covariate matrix of dimension $\tilde{N}_{\text{train}} \times p$ was too large to be fit on a University of Florida HiPerGator2 supercomputer with Intel E5-2698v3 processors and 4 GB of RAM per core. However, the BART and random forests regression models analyzed the full set of covariates. In Tables 1-3, we find that, for most study-group combinations, and irrespective of

Ridge regression					
		Training cases		Test cases	
		B-MSC	Full	B-MSC	Full
Study 1	Group 1	47.4 (1.7)	24.4 (1.6)	47.3 (1.7)	22.4 (1.7)
	Group 2	55.9 (1.6)	30.8 (1.5)	54.3 (1.6)	27.1 (1.6)
	Group 3	57.8 (1.5)	33.5 (1.5)	56.6 (1.5)	29.0 (1.6)
	Group 4	56.4 (1.5)	33.7 (1.4)	53.7 (1.7)	28.5 (1.6)
Study 2	Group 1	56.4 (1.6)	34.7 (1.5)	54.3 (1.8)	31.0 (1.6)
	Group 2	55.5 (1.6)	32.1 (1.5)	54.6 (1.7)	28.4 (1.7)
	Group 3	55.2 (1.5)	36.0 (1.4)	53.9 (1.6)	33.0 (1.5)
	Group 4	56.4 (1.5)	33.1 (1.5)	55.1 (1.7)	30.2 (1.6)

Lasso					
		Training cases		Test cases	
		B-MSC	Full	B-MSC	Full
Study 1	Group 1	41.9 (1.9)	21.2 (1.6)	41.3 (1.9)	19.2 (1.5)
	Group 2	48.6 (1.8)	24.6 (1.5)	47.2 (1.8)	20.2 (1.4)
	Group 3	50.5 (1.8)	26.3 (1.6)	49.4 (1.8)	22.9 (1.6)
	Group 4	50.2 (1.6)	28.2 (1.4)	48.0 (1.8)	24.3 (1.4)
Study 2	Group 1	50.3 (1.7)	27.0 (1.5)	48.4 (1.8)	23.2 (1.4)
	Group 2	50.2 (1.7)	25.7 (1.5)	49.4 (1.7)	21.1 (1.5)
	Group 3	48.3 (1.8)	28.9 (1.5)	46.8 (1.9)	25.2 (1.5)
	Group 4	50.4 (1.8)	25.6 (1.7)	49.2 (1.9)	21.8 (1.6)

Table 2: In the *low association* simulation scenario, accuracy of inferred MPS utilizing the smaller motif submatrices of the proposed B-MSC method as the covariates compared to the high-dimensional set of covariates (“Full”). For **ridge regression** and **lasso** estimation procedures (row block) and study-group combination (row), the displayed numbers are the percentage correlations between the true and estimated MPS of the 360 training and 90 test cases (column blocks), averaged over 500 artificial datasets. Shown in parentheses are the estimated standard errors of the correlations. Separately for the training samples and test samples of each row, a covariate set (B-MSC or Full) with a significantly higher correlation is highlighted in bold.

the regression technique, the lower dimensional predictors provided by B-MSC yielded significantly better MPS estimates for both training and test samples, as evidenced by the significantly higher correlations marked in boldface. In the high association scenario ($\mu = 15$), the results were more strongly in favor of B-MSC; in Tables 2-4 of Supporting Information, B-MSC almost uniformly and significantly outperformed the full set of covariates.

These results demonstrate the success of B-MSC in providing a lower dimensional representation of \mathbf{X} with minimal loss of information, correctly inferring the

Adaptive lasso					
		Training cases		Test cases	
		B-MSC	Full	B-MSC	Full
Study 1	Group 1	44.3 (1.8)	22.2 (1.6)	43.2 (1.9)	20.4 (1.5)
	Group 2	51.5 (1.7)	26.0 (1.4)	49.8 (1.7)	20.9 (1.5)
	Group 3	53.0 (1.6)	29.0 (1.5)	51.6 (1.7)	25.1 (1.6)
	Group 4	51.7 (1.6)	29.1 (1.5)	49.3 (1.8)	24.5 (1.5)
Study 2	Group 1	52.1 (1.7)	28.3 (1.5)	49.7 (1.8)	24.2 (1.4)
	Group 2	52.0 (1.6)	27.7 (1.5)	50.9 (1.7)	22.9 (1.4)
	Group 3	49.5 (1.7)	31.7 (1.5)	48.3 (1.8)	28.3 (1.5)
	Group 4	52.0 (1.8)	28.4 (1.6)	51.1 (1.9)	24.1 (1.7)

Group lasso					
		Training cases		Test cases	
		B-MSC	Full	B-MSC	Full
Study 1	Group 1	44.3 (1.8)	20.5 (1.5)	43.5 (1.8)	18.6 (1.5)
	Group 2	51.0 (1.7)	24.6 (1.4)	49.2 (1.7)	19.7 (1.4)
	Group 3	52.5 (1.7)	26.7 (1.5)	51.4 (1.7)	22.5 (1.6)
	Group 4	52.3 (1.5)	27.9 (1.5)	49.9 (1.7)	23.9 (1.4)
Study 2	Group 1	51.2 (1.7)	26.9 (1.5)	48.7 (1.8)	22.8 (1.4)
	Group 2	51.1 (1.7)	26.3 (1.5)	50.2 (1.7)	21.7 (1.4)
	Group 3	50.2 (1.7)	29.3 (1.5)	48.8 (1.8)	26.4 (1.5)
	Group 4	52.2 (1.7)	25.6 (1.6)	51.3 (1.8)	20.9 (1.6)

Table 3: In the *low association* simulation scenario, accuracy of inferred MPS utilizing the smaller motif submatrices of the proposed B-MSC method as the covariates compared to the high-dimensional set of covariates (“Full”). For **adaptive lasso** and **group lasso** estimation procedures (row block) and study-group combination (row), the displayed numbers are the percentage correlations between the true and estimated MPS of the 360 training and 90 test cases (column blocks), averaged over 500 artificial datasets. Shown in parentheses are the estimated standard errors of the correlations. Separately for the training samples and test samples of each row, a covariate set (B-MSC or Full) with a significantly higher correlation is highlighted in bold.

clique memberships of test cases, and accurately estimating the MPS for subsequent covariate-balanced analyses. This instills confidence in employing the B-MSC technique for analyzing the TCGA data.

5 Integration and analysis of breast cancer datasets

Integrating the TCGA breast cancer patients from the $J = 7$ medical centers, we aimed to compare the overall survival (OS) of $K = 2$ breast cancer subtypes, namely IDC and

Table 4: B-MSc clusters, along with their allocated covariates, that are predictive of multiple propensity score (MPS) in the TCGA breast cancer datasets. See the text for a detailed discussion.

Cluster	Covariate(s)
1	LRRC31, DNMBP-AS1, PYDC1, NPGPR
2	CCNB3
3	RPL29P2, RPS26P11
4	ABCC6P1, SPINK8
5	WFIKKN2
6	OR2T8, OR2W8P
7	GDF3, CST2
8	C1QTNF9B, HBA1
9	LOC100130264, KAAG1
10	OR2L13, TAC2, CLDN19, GRIA4, PROL1, SLC7A3, SLC22A11, RNF186, CDH22
11	P2RY11, KCNG2, Year of initial diagnosis
12	ERVFRD-1, GATA1, CMA1, GCSAML, SIGLEC6, SLC8A3, LOC154544, CTSG, SIGLEC17P, RGS13
13	C14ORF178, ENPP7, HCG4B, PLA2G1B, RNF113B
14	KCNB1, SLC9A8, SPATA2, LINC00651, UBE2V1, CEBPB, PTPN1, FAM65C, MOCS3, PTGIS, B4GALT5, RNF114, snoU13, SNAI1, TMEM189, MIR645, PARD6B, BCAS4, ADNP, DPM1, 4 KCNG1, CBLN4
15	PR+

ILC, among these patients, with the intention of providing insights that can inform the breast cancer population in the United States. An evident challenge is the disparity between the relative percentages of IDC and ILC patients in the U.S., where they stand at 88.9% and 11.1%, respectively [5], which differ much from those in the TCGA studies. For example, the IGC study comprised only 28.9% IDC patients. An effective method for integrative analysis must account for these discrepancies while adjusting for patient attributes such as clinical, demographic, and high-dimensional biomarkers. However, integrative combined (IC) weights [9], like the meta-analytical extensions of most existing weighting methods, assume a hypothetical pseudo-population with equally prevalent subtypes, i.e., 50% IDC and ILC patients, and so does not resemble important aspects of the US patient population. By contrast, the FLEXOR weights [9] guarantee relative weights of 88.9% and 11.1%, in conformity with the subtype prevalence.

We analyzed the TCGA breast cancer datasets containing $N = 450$ patients, covariate matrix $\mathbf{X}^{[1]}$ with $p_1 = 758$ continuous covariates that include mRNA biomarker and clinicopathological measurements, and covariate matrix $\mathbf{X}^{[2]}$ with $p_2 = 522$ binary CNA biomarker and other covariates, so that $p = 1,280$ covariates. For covariate-balanced inferences, the first task was MPS estimation. To implement the proposed B-MSc methodology, we generated MCMC samples from the proposed model using the Supporting Information algorithm. Following a burn-in period of

10,000 MCMC samples, 50,000 additional samples were stored. Posterior convergence was confirmed by trace plots. We applied the previously described inference strategy to find Bayes estimates of the motif submatrices $\Phi^{[1]}$ and $\Phi^{[2]}$ with only $\hat{q}_c^{[1]} = 184$ and $\hat{q}_c^{[2]} = 43$ columns, respectively, corresponding to the estimated clusters. We applied the group lasso technique to regress (S_i, Z_i) on the lower-dimensional motifs of length $\hat{q}_c^{[1]} + \hat{q}_c^{[2]} = 227$ and so obtain the MPS estimates. Table 4 displays the covariates belonging to the 15 (out of 227) B-MS-C clusters that were predictive of MPS. In general, these predictive clusters are very different from the predictors of health outcomes such as cancer survival. Thirteen predictive clusters corresponded to continuous covariates and predominantly comprised mRNA biomarkers. The only exception was the year of initial diagnosis, which (after standardization) exhibited across-patient patterns similar to the genes P2RY11 and KCNG2. The remaining clusters consisted of binary covariates; cluster 14 contained 22 CNA biomarkers and singleton cluster 15 represented positive progesterone receptor status.

The biological relevance of the clusters in Table 4 is attested by the medical literature. As a byproduct of the methodology, regressing only the patient disease subtypes on the motifs gives the B-MS-C clusters that differentiate the disease subtypes. Since out-of-bag prediction, variable selection, and differential analysis are not relevant to MPS estimation, the proposed methodology does not focus on identifying differential covariates. Nevertheless, performing the second regression analysis using group lasso, we discovered the same predictor clusters as Table 4. Comparing with the medical literature, we find each predictor cluster consists of known differential biomarkers of IDC and ILC. Specifically, the biological role of the genes LRRRC31, DNMBP, PYDC1, CCNB3, RPL29P2, RPS26P11, SPINK8, WFIKKN2, OR2T8, GDF3, CST2, C1QTNF9B, HBA1, KAAG1, OR2L13, P2RY11, ERVFRD-1, C14ORF178, and snoU13 has been noted by scientific investigations listed in Supporting Information. [41] show that PR status has an important biological function in differentiating the disease progression of IDC and ILC.

Applying the techniques introduced in [9], we obtained the IC, IGO, and FLEXOR weights for the $N = 450$ patients in the seven TCGA breast cancer datasets. The percent ESS of the IC pseudo-population was 42.2% or 189.7 patients. The percent ESS of the IGO pseudo-population was comparable: 42.1% or 189.3 patients. By contrast, the FLEXOR pseudo-population had a higher percent ESS of 81.1% or 365.0 patients. For FLEXOR, the optimal amounts of aggregated information from the seven datasets, listed in the same order as Table 1 of Supporting Information, were estimated as 22%, 4%, 9%, 13%, 26%, 20%, and 7%, respectively. By contrast, all the study weights are inflexibly set to $\frac{100}{7}\%$ in the IC and IGO pseudo-populations and may be suboptimal for integrative analyses.

We analyzed 500 bootstrap samples of 450 patients drawn with replacement from the TCGA breast cancer database. Side-by-side boxplots of the percent ESS of the three weighting methods are displayed in the left panel of Figure 1. For the bootstrap samples, we find that the FLEXOR pseudo-population had a significantly larger ESS than the other pseudo-populations, indicating this weighting method may be more precise for wide-ranging pseudo-population estimands such as percentiles and comparative group survival features such as differences of the mean or median survival

Table 5: Covariate-specific absolute standardized biases in the TCGA breast cancer studies for three pseudo-populations.

	FLEXOR	IGO	IC
Age at diagnosis	3.6	5.2	4.0
Cancer in nearby lymph nodes	2.8	3.8	3.1
Percentage genome altered	4.0	2.9	3.8
Year of diagnosis	5.8	5.3	5.6
Menopause status 1 or 2	5.1	3.8	5.1
Cancer stage 1 or 2	2.2	2.6	2.1
Positive ER status	3.7	3.2	3.6
Positive PR status	5.2	4.1	5.3
LRRC31	2.9	3.1	3.0
CCNB3	4.8	3.9	4.3
RPL29P2	3.9	3.1	4.1
HBA1	4.6	3.2	4.3




Fig. 1: For 500 bootstrap samples of 450 patients each drawn from the TCGA breast cancer datasets, side-by-side boxplots of the percent ESS (left panel) and absolute standardized bias (right panel) for the IC, IGO, and FLEXOR pseudo-populations.

times. Boxplots of the absolute standardized bias [4] are shown in the right panel of Figure 1. A smaller ASB is indicative of better covariate balance. We find that the weighting methods are equally effective in mitigating imbalances in the large number of covariates. We observe a comparable outcome in Table 5, showing the ASBs of certain covariates from the TCGA database. Finally, estimates of the survival functions of the $K = 2$ disease subtypes (IDC and ILC) were meta-analyzed using different weighting methods as follows. BKME (1) was evaluated using these quantities. Uncertainty estimation was based on $B = 500$ bootstrap samples.

Adjusting for stages and grades, Figures 2A–2C provide unconfounded OS curves for IDC and ILC patients using three different weighting methods: IC, IGO, and FLEXOR. Our findings reveal that the IC and IGO weighting methods yield similar




Fig. 2: For the TCGA breast cancer patients, estimated overall survival (OS) curves for disease subtypes IDC (red, solid lines) and ILC (cyan, dashed lines) with integrative combined (IC), integrative generalized overlap (IGO), and FLEXOR weights. The standard error bands were estimated from 500 bootstrap samples and are shown in pink and light cyan respectively for IDC and ILC.

conclusions regarding survival times, somewhat inconclusively concluding that IDC generally has a poorer prognosis than ILC, except possibly for lower OS. Notably, both subtypes show survival probabilities exceeding 50%. In contrast, the FLEXOR weighting method indicates significantly worse health outcomes for IDC compared to the other methods. For instance, the 10th percentile of OS for IC, IGO, and FLEXOR weights were 55.0, 55.8, and 46.4 months, respectively—highlighting statistically significant differences when accounting for standard errors. More importantly, FLEXOR consistently suggests that IDC has uniformly worse outcomes than ILC, regardless of OS, with a median IDC survival time of 122.7 months (SE: 0.1 months). The difference in results may be attributed to the considerably lower ESS and somewhat unrealistic assumptions (e.g., assuming equally prevalent disease subtypes) of the IC and IGO pseudo-populations. This raises questions about the validity of IC and IGO inferences for these datasets, emphasizing the need for careful consideration of methodological

assumptions and their potential impact on study outcomes. Conversely, identifying IDC as consistently associated with poorer outcomes than ILC (Figure 2C) could pave the way for more precise and targeted therapeutic interventions, potentially benefiting both patient groups.

6 Conclusion

Propensity scores play a pivotal role, serving as the foundation for weighting or matching methods for covariate-balanced analyses. A primary barrier for integrating retrospective cohorts is covariate imbalance across the studies and groups. In the context of integrative analyses encompassing multiple observational studies with diverse and unbalanced groups, the concept of propensity scores was generalized by [9] to the multiple propensity score (MPS); this is defined as the probability of a study-group combination given the subject’s covariates. However, the presence of high-dimensional covariates introduces complexity in estimating the MPS and, consequently, poses a challenge in integrating observational studies.

We have proposed a novel, hybrid Bayesian-frequentist technique called B-MS. Exploiting the dimension-reduction property of non-parametric CRPs, we discover latent lower-dimensional archetypes in the covariates called motifs. Using these motifs as potential regressors, standard regularization techniques can be employed to accurately and flexibly estimate the propensity scores. Using a computationally efficient MCMC algorithm, we foster an inferential procedure that discovers motif matrices associated with high-dimensional covariates to accurately estimate the MPS. We then apply these techniques to make covariate-balanced weighted inferences using censored survival outcomes in integrative analyses of high-dimensional TCGA breast cancer studies.

There are two main reasons for defining a separate matrix $\mathbf{X}^{[t]}$ for factor covariates with different A_t for $t > 1$, instead of combining all the factor covariates into a single matrix $\mathbf{X}^{[2]}$. *First*, from a scientific perspective, the factor covariates are often created from more basic, and often continuous, measurements by choosing a predetermined number of thresholds informed by biological knowledge. For example, in the motivating TCGA application, the CNA measurements are coarsened as binary factors. In a different application, it may be more reasonable to create factor variables with $A = 3$ levels using the same CNA measurements, and we would then expect the latent cluster structure, including the number of clusters, to depend on the chosen number of levels. In other words, the CRP prior that drives the cluster structure depends on A_t , necessitating different CRP priors for different $\mathbf{X}^{[t]}$. *Second*, from a purely modeling perspective, as discussed in Section 2.1, the prior for the factor motif submatrix utilizes a generalized Bernoulli or categorical distribution on A_t categories with a corruption probability matrix of dimension $A_t \times A_t$. For these reasons, it is appropriate to assume separate factor matrices $\mathbf{X}^{[t]}$ for different A_t when $t > 1$.

The B-MS methodology is capable of accommodating a blend of retrospective cohorts and RCTs. In future research, we will extend this strategy to transportability [42] and data-fusion [43] problems, which utilize random samples from the natural

population. R code implementing the proposed method is available on GitHub at <https://github.com/sguha-lab/CRP>

Supplementary information. Web Appendices, Tables, and Figures referenced in Sections A and B are available in “Supporting Information.”

Acknowledgements. This work was supported by the National Science Foundation under award DMS-1854003 to SG, and by the National Institutes of Health under award CA269398 to SG and YL, and awards CA209414 and CA249096 to YL.

Declarations

- Conflict of interest/Competing interests: None

References

- [1] Smith, C.J., Minas, T.Z., Ambs, S.: Analysis of tumor biology to advance cancer health disparity research. *The American Journal of Pathology* **188**(2), 304–316 (2018)
- [2] Robins, J.M., Rotnitzky, A.: Semiparametric efficiency in multivariate regression models with missing data. *Journal of the American Statistical Association* **90**(429), 122–129 (1995)
- [3] Rosenbaum, P.R., Rubin, D.B.: The central role of the propensity score in observational studies for causal effects. *Biometrika* **70**(1), 41–55 (1983)
- [4] Li, F., Morgan, K.L., Zaslavsky, A.M.: Balancing covariates via propensity score weighting. *Journal of the American Statistical Association* **113**(521), 390–400 (2018)
- [5] NCI: Genomic Data Commons Data Portal. <https://portal.gdc.cancer.gov/> (2022)
- [6] Schmidt, K.T., Chau, C.H., Price, D.K., Figg, W.D.: Precision oncology medicine: the clinical relevance of patient-specific biomarkers used to optimize cancer treatment. *The Journal of Clinical Pharmacology* **56**(12), 1484–1499 (2016)
- [7] Barroso-Sousa, R., Metzger-Filho, O.: Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications. *Therapeutic Advances in Medical Oncology* **8**(4), 261–266 (2016)
- [8] Shu, D., Han, P., Wang, R., Toh, S.: Estimating the marginal hazard ratio by simultaneously using a set of propensity score models: A multiply robust approach. *Statistics in Medicine* **40**(5), 1224–1242 (2021)
- [9] Guha, S., Li, Y.: Causal meta-analysis by integrating multiple observational studies with multivariate outcomes. *Biometrics* **80**(3) (2024)

- [10] Hilt, D.E., Seegrist, D.W.: Ridge, a computer program for calculating ridge regression estimates. Department of Agriculture, Forest Service, Northeastern Forest Experiment Station (1977)
- [11] Tibshirani, R.: The lasso method for variable selection in the Cox model. *Statistics in Medicine* **16**, 385–395 (1997)
- [12] Zou, H.: The adaptive lasso and its oracle properties. *Journal of the American Statistical Association* **101**, 1418–1429 (2006)
- [13] Meier, L., Van De Geer, S., Bühlmann, P.: The group lasso for logistic regression. *Journal of the Royal Statistical Society Series B: Statistical Methodology* **70**(1), 53–71 (2008)
- [14] Yi, G.Y., Chen, L.-P.: Estimation of the average treatment effect with variable selection and measurement error simultaneously addressed for potential confounders. *Statistical Methods in Medical Research* **32**(4), 691–711 (2023)
- [15] Chen, L.-P., Hsu, W.-H.: Chemist: An r package for causal inference with high-dimensional error-prone covariates and misclassified treatments. *Japanese Journal of Statistics and Data Science*, 1–17 (2023)
- [16] Linero, A.R., Antonelli, J.L.: The how and why of Bayesian nonparametric causal inference. *Wiley Interdisciplinary Reviews: Computational Statistics* **15**(1), 1583 (2023)
- [17] Li, F., Ding, P., Mealli, F.: Bayesian causal inference: a critical review. *Philosophical Transactions of the Royal Society A* **381**(2247), 20220153 (2023)
- [18] Oganisian, A., Roy, J.A.: A practical introduction to Bayesian estimation of causal effects: Parametric and nonparametric approaches. *Statistics in medicine* **40**(2), 518–551 (2021)
- [19] Hill, J., Linero, A., Murray, J.: Bayesian additive regression trees: A review and look forward. *Annual Review of Statistics and Its Application* **7**, 251–278 (2020)
- [20] Antonelli, J., Parmigiani, G., Dominici, F.: High-dimensional confounding adjustment using continuous spike and slab priors. *Bayesian Analysis* **14**(3), 805 (2019)
- [21] Park, T., Casella, G.: The Bayesian Lasso. *Journal of the American Statistical Association* **103**(482), 681–686 (2008) <https://doi.org/10.1198/016214508000000337> <https://doi.org/10.1198/016214508000000337>
- [22] Zigler, C.M.: The central role of Bayes’ theorem for joint estimation of causal effects and propensity scores. *The American Statistician* **70**(1), 47–54 (2016)

- [23] Chipman, H.A., George, E.I., McCulloch, R.E.: BART: Bayesian additive regression trees. *The Annals of Applied Statistics* **4**(1), 266–298 (2010) <https://doi.org/10.1214/09-AOAS285>
- [24] Guha, S., Baladandayuthapani, V.: A nonparametric Bayesian technique for high-dimensional regression. *Electronic Journal of Statistics* **10**(2), 3374–3424 (2016)
- [25] Lijoi, A., Prünster, I.: Models beyond the dirichlet process. In: *Bayesian Non-parametrics*, pp. 80–136. Cambridge Series in Statistical and Probabilistic Mathematics, Cambridge, U.K. (2010)
- [26] Müller, P., Mitra, R.: Bayesian nonparametric inference– why and how. *Bayesian Analysis (Online)* **8**(2) (2013)
- [27] Imbens, G.W.: The role of the propensity score in estimating dose-response functions. *Biometrika* **87**(3), 706–710 (2000)
- [28] Dahl, D.B.: Model-Based Clustering for Expression Data via a Dirichlet Process Mixture Model, pp. 201–218. Cambridge University Press, Cambridge, U.K. (2006). <https://doi.org/10.1017/CBO9780511584589.011>
- [29] Müller, P., Quintana, F., Rosner, G.L.: A product partition model with regression on covariates. *Journal of Computational and Graphical Statistics* **20**, 260–278 (2011)
- [30] Lee, J., Müller, P., Zhu, Y., Ji, Y.: A nonparametric Bayesian model for local clustering With application to proteomics. *Journal of the American Statistical Association* **108**, 775–788 (2013)
- [31] Guha, S., Jung, R., Dunson, D.: Predicting phenotypes from brain connection structure. *Journal of the Royal Statistical Society: Series C (Applied Statistics)* **71**(4), 639–668 (2022)
- [32] Mundade, R., Imperiale, T.F., Prabhu, L., Loehrer, P.J., Lu, T.: Genetic pathways, prevention, and treatment of sporadic colorectal cancer. *Oncoscience* **1**(6), 400 (2014)
- [33] Kim, S., Tadesse, M.G., Vannucci, M.: Variable selection in clustering via Dirichlet process mixture models. *Biometrika* **93**(4), 877–893 (2006)
- [34] Dunson, D.B., Herring, A.H., Engel, S.M.: Bayesian selection and clustering of polymorphisms in functionally-related genes. *Journal of the American Statistical Association* **103**, 534–546 (2008)
- [35] Ghosal, S., Ghosh, J.K., Ramamoorthi, R.V.: Posterior consistency of Dirichlet mixtures in density estimation. *The Annals of Statistics* **27**, 143–158 (1999)
- [36] Li, F., Li, F.: Propensity score weighting for causal inference with multiple

- treatments. *The Annals of Applied Statistics* **13**(4), 2389–2415 (2019)
- [37] Crump, R.K., Hotz, V.J., Imbens, G.W., Mitnik, O.A.: Moving the goalposts: addressing limited overlap in the estimation of average treatment effects by changing the estimand. Technical report, National Bureau of Economic Research (2006)
- [38] Li, L., Greene, T.: A weighting analogue to pair matching in propensity score analysis. *The International Journal of Biostatistics* **9**(2), 215–234 (2013)
- [39] Xie, J., Liu, C.: Adjusted Kaplan–Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. *Statistics in Medicine* **24**(20), 3089–3110 (2005)
- [40] Fleming, T.R., Harrington, D.P.: *Counting Processes and Survival Analysis*. John Wiley & Sons, Hoboken, New Jersey (2011)
- [41] Richer, J.K., Jacobsen, B.M., Manning, N.G., Abel, M.G., Horwitz, K.B., Wolf, D.M.: Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. *Journal of Biological Chemistry* **277**(7), 5209–5218 (2002)
- [42] Westreich, D., Edwards, J.K., Lesko, C.R., Stuart, E., Cole, S.R.: Transportability of trial results using inverse odds of sampling weights. *American Journal of Epidemiology* **186**(8), 1010–1014 (2017)
- [43] Dahabreh, I.J., Robertson, S.E., Petito, L.C., Hernán, M.A., Steingrimsson, J.A.: Efficient and robust methods for causally interpretable meta-analysis: Transporting inferences from multiple randomized trials to a target population. *Biometrics* **79**(2), 1057–1072 (2023)